Tests:Estradiol, Serum: Difference between revisions
- Department
- Biochemistry
Tests:Estradiol, Serum
No edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
17 beta estradiol | 17 beta estradiol | ||
|- | |- | ||
| | |Availability | ||
|Monday to Friday | |Monday to Friday | ||
Weekend testing to be arranged | Weekend testing to be arranged | ||
| Line 35: | Line 35: | ||
== Specimen Requirements == | == Specimen Requirements == | ||
|- | |- | ||
|Specimen | |Specimen | ||
|Serum | |Serum | ||
Plasma | Plasma | ||
|- | |- | ||
|Preferred | |Preferred | ||
| Line 50: | Line 47: | ||
|- | |- | ||
|Unacceptable | |Unacceptable | ||
| | |||
|- | |||
|Specimen Transportation | |||
| | | | ||
|- | |- | ||
| Line 58: | Line 58: | ||
== Aliquot Requirements == | == Aliquot Requirements == | ||
|- | |- | ||
|Sample | |Sample | ||
|Serum | |Serum | ||
|- | |||
|Preferred Volume | |||
| | |||
|- | |- | ||
|Minimum Volume | |Minimum Volume | ||
Revision as of 14:03, 20 March 2025
Overview | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Department | Biochemistry | ||||||||||||
| Test Code | TOES | ||||||||||||
| Synonyms | Oestradiol
Estradiol E2 17 beta estradiol | ||||||||||||
| Availability | Monday to Friday
Weekend testing to be arranged | ||||||||||||
| Turnaround Time | 2 hrs – 2 days | ||||||||||||
| Stability – Add test | |||||||||||||
Specimen Requirements | |||||||||||||
| Specimen | Serum
Plasma | ||||||||||||
| Preferred | 6 mL Plain Red-Top | ||||||||||||
| Acceptable | 5mL Yellow-Top | ||||||||||||
| Unacceptable | |||||||||||||
| Specimen Transportation | |||||||||||||
| Paediatric Requirements | 0.5 mL in a Red-Top or Yellow-Top tube | ||||||||||||
Aliquot Requirements | |||||||||||||
| Sample | Serum | ||||||||||||
| Preferred Volume | |||||||||||||
| Minimum Volume | 200ul | ||||||||||||
| Aliquot Transportation | |||||||||||||
Clinical Information | |||||||||||||
| Reference Intervals |
| ||||||||||||
| Test Method | Abbott Alinity Ci analyser using Abbott immunoassay reagent. | ||||||||||||
| Advanced Notice | |||||||||||||
| Patient Preparation | |||||||||||||
Comments | |||||||||||||
| Samples from patients receiving oestrogen replacement therapy including Premarin may yield spurious oestradiol results.
| |||||||||||||